• Increase font size
  • Default font size
  • Decrease font size

Hi-Tech Pharmacal to Release Fourth Quarter Earnings and Hold Conference Call on July 14, 2009

Print E-mail
Friday, 10 July 2009 08:00

AMITYVILLE, N.Y.--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its fourth quarter of Fiscal Year 2009 ended April 30, 2009, prior to the market opening on Tuesday July 14, 2009 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time.

To access the conference call, dial toll free 866-383-8003, or 617-597-5330 for international callers, five minutes before the conference. The passcode of the conference call is 49044098.

A replay of the conference call will be available after 12 p.m. on July 14, 2009, for one week by calling toll free 888-286-8010, or 617-801-6888 for international callers. The passcode for the replay is 27915077.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace. Hi-Tech’s ECR Pharmaceuticals division markets branded prescription products.




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 3 hours ago Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 3 hours ago Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 8 hours ago Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 13 hours ago $CVM up 17% and technically looks like it may head higher.
about 18 hours ago $ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
about 19 hours ago Catalysts on tap for Corcept: Corcept Therapeutics (NASDAQ:CORT) is a drug discovery company focused on the deve... http://t.co/jd3C1ddH
about 20 hours ago Commented on: "Will Celsion's Upcoming Catalysts Help The Price Break-Out Stick?" http://t.co/dJ0reUFR $BSX $PHG $MDSO $CLSN
about 20 hours ago Monday morning watch -- European Leaders Maintain Pressure on Greece to Complete Terms for Bailout - http://t.co/0wipY6QB via @BloombergNews

navigation

Free Phone Trade Alerts